Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Inclusion Criteria: * Age 18-70 years * Histological diagnosis of prostate adenocarcinoma * Stage ≥T2b for which surgery is indicated * No distant metastasis (M0) * NLR ≥3 in the blood or NLR ≥3 in the tumor biopsies or a percentage of MDSCs ≥ 30% in the tumour biopsies * PS (ECOG scale) 0-1 * Adequate hepatic function: ALT and ASAT ≤ 2.5 x ULN, Bilirubin ≤ 1.5 ULN (exception if Gilbert's syndrome ≤ 2.5 x ULN) * Adequate renal function: calculated creatinine clearance ≥ 50 ml/min according to the formula of Cockcroft-Gault * Hemoglobin ≥ 10 g/dl, leukocyte count ≥ 4.0 x 103/µl, platelet count ≥ 200 x 103/µl * Informed Consent as documented by the patient's signature Exclusion Criteria: * No history of coagulation disorders and normal INR * Significant cardiovascular disorders in the last 12 months * Other clinically significant concomitant disease states which in the opinion of the Investigator may represent contraindications to study participation * Known or suspected non-compliance * Participation in another study with investigational drug within the 30 days preceding and during the present study * Ongoing treatment with strong CYP3A4 inhibitors or dual CYP2C9 and CYP3A4 inhibitors